secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001601485-25-000022
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics appoints Preetam Shah as Chief Strategy and Financial Officer
--------------------------------------------------------------------------------

- Preetam Shah appointed Chief Strategy and Financial Officer effective March 24, 2025; will become Principal Financial Officer and Principal Accounting Officer on April 1, 2025.
- Annual base salary $480,000; target bonus of 40% of base; initial option grant equal to 1.2% of outstanding shares as of April 15, 2025, vesting over 4 years.
- Shah previously served as CFO/CBO at Cidara Therapeutics (Sept 2021–Feb 2025) and CFO & Treasurer at Brainstorm Cell Therapeutics (Sept 2019–Aug 2021).
- The company highlights upcoming Phase 2 AMPLIFY-7P disease-free survival interim analysis for cancer immunotherapy ELI-002.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/0001601485-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000022/angn-20250321.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer